Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab-Reference-Cited by-同舟云学术

Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab

Published:2024-03-23 Issue:5 Volume:19 Page:185-198
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Agostini Maria L¹,Schnell Gretja¹,Iulio Julia di¹^ORCID,Kohli Anita²,Shapiro Adrienne E³^ORCID,Sarkis Elias H⁴^ORCID,Givens Naomi⁵,Peppercorn Amanda⁶,Skingsley Andrew⁵,Gaffney Leah A¹,Aldinger Melissa¹,Hebner Christy M¹,Cathcart Andrea L¹^ORCID

Affiliation:

1. Vir Biotechnology, Inc., San Francisco, CA, USA

2. The Institute for Liver Health – Tucson, Phoenix, Arizona, USA

3. University of Washington & Fred Hutchinson Cancer Center, Seattle, Washington, USA

4. Sarkis Clinical Trials, Gainesville, FA, USA

5. GSK, London, UK

6. GSK, Cambridge, MA, USA

Funder

GlaxoSmithKline

Vir Biotechnology, Inc.

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460794.2024.2350923

Reference38 articles.

1. World Health Organization (WHO). COVID-19 dashboard [Internet]. Geneva (Switzerland): WHO; 2023 [cited 2023 Jun 22]. Available from: https://covid19.who.int/

2. National Institute of Health (NIH). COVID-19 treatment guidelines: clinical spectrum of SARS-CoV-2 infection [Internet]. Bethesda (MD): NIH; 2024 [cited 2023 Feb 15]. Available from: www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/

3. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

4. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

5. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis